SG11201907840RA - Fused imidazo-piperidine jak inhibitors - Google Patents
Fused imidazo-piperidine jak inhibitorsInfo
- Publication number
- SG11201907840RA SG11201907840RA SG11201907840RA SG11201907840RA SG11201907840RA SG 11201907840R A SG11201907840R A SG 11201907840RA SG 11201907840R A SG11201907840R A SG 11201907840RA SG 11201907840R A SG11201907840R A SG 11201907840RA SG 11201907840R A SG11201907840R A SG 11201907840RA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- san francisco
- pct
- street
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
HNN N (I) W O 18/ 165 395 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT oimiolo VIII °nolo VIII 011101110111 H imio oimIE (10) International Publication Number WO 2018/165395 Al (51) International Patent Classification: CO7D 471/04 (2006.01) A61K 31/437 (2006.01) A61P 11/00 (2006.01) (21) International Application Number: PCT/US2018/021492 (22) International Filing Date: 08 March 2018 (08.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/469,073 09 March 2017 (09.03.2017) US (71) Applicant: THERAVANCE BIOPHARMA R&D IP, LLC [US/US]; 901 Gateway Boulevard, South San Fran- cisco, California 94080 (US). (72) Inventors: FATHEREE, Paul R.; 921 Minnesota Street, San Francisco, California 94107 (US). BRANDT, Gary E.L.; 2160 Buena Vista Avenue, Alameda, California 94501 (US). SMITH, Cameron; 4256 Shelter Creek Lane, San Bruno, California 94066 (US). SULLIVAN, Steven D.E.; 1417 17th Avenue, San Francisco, California 94122 (US). VAN ORDEN, Lori Jean; 3 Whitney Street, San Francisco, California 94131 (US). KLEINSCHEK, Melanie A.; 30 Elizabeth Street, San Francisco, California 94110 (US). CRATER, Glenn D.; 7108 Rippling Stone Ln, Raleigh, North Carolina 27612 (US). (74) Agent: HAGENAH, Jeffrey A. et al.; Theravance Biophar- ma US, Inc., 901 Gateway Boulevard, South San Francisco, California 94080 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS (57) : The invention provides compounds of formula (I): (I) where the vari- ables are defined in the specification, or a pharmaceutically-acceptable salt thereof, HO that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such com- pounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469073P | 2017-03-09 | 2017-03-09 | |
| PCT/US2018/021492 WO2018165395A1 (en) | 2017-03-09 | 2018-03-08 | Fused imidazo-piperidine jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907840RA true SG11201907840RA (en) | 2019-09-27 |
Family
ID=61683956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907544VA SG11201907544VA (en) | 2017-03-09 | 2018-03-08 | Jak inhibitors containing a 4-membered heterocyclic amide |
| SG11201907840RA SG11201907840RA (en) | 2017-03-09 | 2018-03-08 | Fused imidazo-piperidine jak inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907544VA SG11201907544VA (en) | 2017-03-09 | 2018-03-08 | Jak inhibitors containing a 4-membered heterocyclic amide |
Country Status (20)
| Country | Link |
|---|---|
| US (10) | US10196393B2 (en) |
| EP (2) | EP3592743A1 (en) |
| JP (2) | JP7134990B2 (en) |
| KR (2) | KR102533646B1 (en) |
| CN (2) | CN110461839B (en) |
| AR (2) | AR111241A1 (en) |
| AU (2) | AU2018231032B2 (en) |
| BR (2) | BR112019018649A2 (en) |
| CA (1) | CA2997772A1 (en) |
| DK (1) | DK3592742T3 (en) |
| EA (2) | EA037261B1 (en) |
| ES (1) | ES2882186T3 (en) |
| IL (2) | IL268679B (en) |
| MX (2) | MX2019010541A (en) |
| PH (2) | PH12019501941A1 (en) |
| PT (1) | PT3592742T (en) |
| SG (2) | SG11201907544VA (en) |
| TW (2) | TWI754019B (en) |
| WO (2) | WO2018165392A1 (en) |
| ZA (2) | ZA201905585B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108349972B (en) | 2015-11-03 | 2021-06-08 | 施万生物制药研发Ip有限责任公司 | JAK kinase inhibitor compounds for the treatment of respiratory diseases |
| DK3371185T3 (en) * | 2015-11-03 | 2020-11-30 | Topivert Pharma Ltd | 4,5,6,7-TETRAHYDRO-1H-IMIDAZO [4,5-C] PYRIDINE AND 1,4,5,6,7,8-HEXAHYDROIMIDAZO [4,5-D] AZEPINE DERIVATIVES AS JANUS CHINASE INHIBITORS |
| CA2997772A1 (en) * | 2017-03-09 | 2018-09-09 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine jak inhibitors |
| AR111495A1 (en) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | FUSIONED IMIDAZO-PIPERIDINE COMPOUNDS AS JAK INHIBITORS |
| EP3609498A1 (en) | 2017-05-01 | 2020-02-19 | Theravance Biopharma R&D IP, LLC | Methods of treatment using a jak inhibitor compound |
| AU2019335200A1 (en) | 2018-09-04 | 2021-03-11 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as JAK inhibitors |
| IL281146B2 (en) * | 2018-09-04 | 2023-12-01 | Theravance Biopharma R& D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| JP2021535176A (en) | 2018-09-04 | 2021-12-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Process for preparing JAK inhibitors and their intermediates |
| JP2022506111A (en) * | 2018-10-29 | 2022-01-17 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 2-Azabicyclohexane compound as a JAK inhibitor |
| KR20210132666A (en) * | 2019-02-25 | 2021-11-04 | 허난 메디노 파마슈티컬 테크놀로지 컴퍼니 리미티드 | JAK inhibitor compounds and their use |
| KR20210137087A (en) | 2019-03-05 | 2021-11-17 | 인사이트 코포레이션 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| EP4071145A4 (en) * | 2019-12-30 | 2023-04-19 | Liang Lu | Jak inhibitor compound and use thereof |
| TW202144343A (en) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Crystalline hydrate of a jak inhibitor compound |
| EP3944859A1 (en) * | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| WO2022178215A1 (en) * | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| EP4359402A1 (en) * | 2021-06-25 | 2024-05-01 | Theravance Biopharma R&D IP, LLC | Imidazolo indazole compounds as jak inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (en) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Indazole derivative having ttk inhibitory action |
| JP5651681B2 (en) | 2009-04-03 | 2015-01-14 | 大日本住友製薬株式会社 | Compounds for the treatment of metabotropic glutamate receptor 5-mediated disorders and methods of use thereof |
| DK3001903T3 (en) | 2009-12-21 | 2017-12-18 | Samumed Llc | 1H-PYRAZOLO [3,4 -?] PYRIDINES AND THERAPEUTIC APPLICATIONS THEREOF |
| EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| SI3318565T1 (en) | 2013-12-05 | 2021-07-30 | Pfizer Inc. | Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides |
| CN106459048A (en) | 2014-05-14 | 2017-02-22 | 辉瑞公司 | Pyrazolopyridines and pyrazolopyrimidines |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (en) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | Tnik ikk tbk1 pyrazole derivatives as tnik ikk and tbk1 inhibitor and pharmaceutical composition comprising same |
| DK3371185T3 (en) | 2015-11-03 | 2020-11-30 | Topivert Pharma Ltd | 4,5,6,7-TETRAHYDRO-1H-IMIDAZO [4,5-C] PYRIDINE AND 1,4,5,6,7,8-HEXAHYDROIMIDAZO [4,5-D] AZEPINE DERIVATIVES AS JANUS CHINASE INHIBITORS |
| EP3712152B1 (en) | 2015-11-03 | 2021-01-13 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| CN108349972B (en) | 2015-11-03 | 2021-06-08 | 施万生物制药研发Ip有限责任公司 | JAK kinase inhibitor compounds for the treatment of respiratory diseases |
| CA2997772A1 (en) | 2017-03-09 | 2018-09-09 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine jak inhibitors |
| AR111495A1 (en) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | FUSIONED IMIDAZO-PIPERIDINE COMPOUNDS AS JAK INHIBITORS |
| EP3609498A1 (en) | 2017-05-01 | 2020-02-19 | Theravance Biopharma R&D IP, LLC | Methods of treatment using a jak inhibitor compound |
| TWI808083B (en) | 2017-05-01 | 2023-07-11 | 美商施萬生物製藥研發 Ip有限責任公司 | Crystalline forms of a jak inhibitor compound |
| KR102032418B1 (en) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient |
| AU2019335200A1 (en) | 2018-09-04 | 2021-03-11 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as JAK inhibitors |
| IL281146B2 (en) | 2018-09-04 | 2023-12-01 | Theravance Biopharma R& D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| JP2021535176A (en) | 2018-09-04 | 2021-12-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Process for preparing JAK inhibitors and their intermediates |
-
2018
- 2018-03-08 CA CA2997772A patent/CA2997772A1/en active Pending
- 2018-03-08 AR ARP180100542A patent/AR111241A1/en unknown
- 2018-03-08 WO PCT/US2018/021489 patent/WO2018165392A1/en unknown
- 2018-03-08 TW TW107107939A patent/TWI754019B/en active
- 2018-03-08 CN CN201880017046.0A patent/CN110461839B/en active Active
- 2018-03-08 BR BR112019018649A patent/BR112019018649A2/en unknown
- 2018-03-08 AR ARP180100543A patent/AR111242A1/en unknown
- 2018-03-08 PT PT187117965T patent/PT3592742T/en unknown
- 2018-03-08 EA EA201992126A patent/EA037261B1/en not_active IP Right Cessation
- 2018-03-08 US US15/915,418 patent/US10196393B2/en active Active
- 2018-03-08 EP EP18712398.9A patent/EP3592743A1/en active Pending
- 2018-03-08 TW TW107107936A patent/TWI779016B/en active
- 2018-03-08 JP JP2019548369A patent/JP7134990B2/en active Active
- 2018-03-08 AU AU2018231032A patent/AU2018231032B2/en active Active
- 2018-03-08 KR KR1020197029543A patent/KR102533646B1/en active IP Right Grant
- 2018-03-08 JP JP2019548449A patent/JP6974487B2/en active Active
- 2018-03-08 SG SG11201907544VA patent/SG11201907544VA/en unknown
- 2018-03-08 AU AU2018231035A patent/AU2018231035B2/en active Active
- 2018-03-08 CN CN201880016693.XA patent/CN110382498B/en active Active
- 2018-03-08 US US15/915,434 patent/US10208040B2/en active Active
- 2018-03-08 BR BR112019018648-4A patent/BR112019018648A2/en unknown
- 2018-03-08 WO PCT/US2018/021492 patent/WO2018165395A1/en unknown
- 2018-03-08 KR KR1020197029560A patent/KR102526764B1/en active IP Right Grant
- 2018-03-08 EA EA201992128A patent/EA037748B1/en unknown
- 2018-03-08 MX MX2019010541A patent/MX2019010541A/en unknown
- 2018-03-08 ES ES18711796T patent/ES2882186T3/en active Active
- 2018-03-08 SG SG11201907840RA patent/SG11201907840RA/en unknown
- 2018-03-08 MX MX2019010539A patent/MX2019010539A/en unknown
- 2018-03-08 DK DK18711796.5T patent/DK3592742T3/en active
- 2018-03-08 EP EP18711796.5A patent/EP3592742B1/en active Active
- 2018-12-17 US US16/222,647 patent/US10392386B2/en active Active
- 2018-12-19 US US16/225,473 patent/US10519153B2/en active Active
-
2019
- 2019-07-15 US US16/511,410 patent/US10550118B2/en active Active
- 2019-08-13 IL IL268679A patent/IL268679B/en unknown
- 2019-08-13 IL IL268689A patent/IL268689B2/en unknown
- 2019-08-22 PH PH12019501941A patent/PH12019501941A1/en unknown
- 2019-08-23 ZA ZA2019/05585A patent/ZA201905585B/en unknown
- 2019-08-26 ZA ZA2019/05618A patent/ZA201905618B/en unknown
- 2019-08-29 PH PH12019501985A patent/PH12019501985A1/en unknown
- 2019-11-11 US US16/679,676 patent/US11254669B2/en active Active
- 2019-12-03 US US16/701,426 patent/US10954237B2/en active Active
-
2021
- 2021-02-12 US US17/248,907 patent/US11453668B2/en active Active
-
2022
- 2022-01-14 US US17/576,089 patent/US11667637B2/en active Active
- 2022-08-10 US US17/885,475 patent/US11878977B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201903348UA (en) | Therapeutic compounds and methods of use thereof | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |